KRON: kronosbio.com Amount of Cash per Share

Corporate emblem and logo of Kronos Bio, Inc. (KRON)

Cash per share trends demonstrate the potential of Kronos Bio, Inc. (KRON) target cancer therapy with low finished product manufacturing costs. The current metric has reached 1.63, which is critical for a company with an academic approach to transcriptional research and a strong roster of scientists. However, the absence of sales is leading to a gradual depletion of capital and the necessity for external financing.

KRON: Kronos Bio Inc Cash per Share 07/04/2022 - 06/28/2025

Analytical breakdowns for Kronos Bio, Inc.

- market price and analyst price targets:
- cash position and cash flow details:
Summary company analysis:KRON, Kronos Bio Corporation
Original product of kronosbio.com

Professional capital evaluates the profile of Kronos Bio, Inc. (KRON) through the lens of operational viability. The cash per share metric reflects the daily liquidity balance, demonstrating the rate of capital burn. A decline in this line warns of a potential cash gap risk, while an excess indicates investment inefficiency. For a leader in cancer therapy, this is a critical funding marker for costly research into transcription factors. The stability of this metric confirms the asset's reliability.